key: cord-0884151-5fb03d8c authors: Mancini, Fabiola; Barbanti, Fabrizio; Scaturro, Maria; Fontana, Stefano; Di Martino, Angela; Marsili, Giulia; Puzelli, Simona; Calzoletti, Laura; Facchini, Marzia; Di Mario, Giuseppina; Fabiani, Concetta; DSTAT, Antonino Bella; Riccardo, Flavia; DSTAT, Patrizio Pezzotti; Stefanelli, Paola; Rezza, Giovanni; Ciervo, Alessandra title: Multiplex rt-Real Time PCR assays for diagnostic testing of SARS-CoV-2 and seasonal influenza viruses. A challenge of the phase 3 pandemic setting date: 2020-10-20 journal: J Infect Dis DOI: 10.1093/infdis/jiaa658 sha: 93a5a63df8385aeed8d855efe83d44ac5e4d9467 doc_id: 884151 cord_uid: 5fb03d8c BACKGROUND: Pandemic COVID-19 disease represents a challenge for health-care structures and the molecular confirmation of samples from infected individuals is crucial and therefore guides public health decision making. Clusters and possibly increased diffuse transmission could occur in the context of the next influenza season. For this reason, a diagnostic test able to discriminate SARS-CoV-2 from influenza viruses is urgently needed. METHODS: A multiplex rt-Real Time PCR assay was assessed using one laboratory protocol with different Real Time PCR instruments. Overall, 1,000 clinical samples (600 samples SARS-CoV-2 infected patients, 200 samples from influenza infected patients and 200 negative samples) were analyzed. RESULTS: The assay developed was able to detect and discriminate each virus target, and to intercept co-infections. The limit of quantification of each assay ranged between 5 and 10 genomic copy numbers, with a cutoff value of 37.7 and 37.8 for influenza and SARS-CoV-2 viruses, respectively. Only two influenza co-infections were detected in COVID-19 samples. CONCLUSIONS: This study suggests that multiplex assay is a rapid, valid, and accurate method for the detection of SARS-CoV-2 and influenza viruses in clinical samples. The test may be an important diagnostic tool for both diagnostic and surveillance purposes during the seasonal influenza activity period. A c c e p t e d M a n u s c r i p t BACKGROUND After the first reported outbreak in Wuhan in December 2019, SARS-CoV-2, the cause of COVID-19, has swept most countries in five continents. In February and March 2020, the novel coronavirus rapidly spread in Europe, where affected countries introduced stringent lockdown measures to contain epidemic [1, 2] . With over 35 million confirmed cases and 1million deaths, reported to World Health Organization (WHO) as of the 5 th of October 2020 (https://covid19.who.int), the SARS-CoV-2 pandemic is causing a global health emergency which is expected to continue in the coming months pending the development of effective pharmacological measures. Early detection of cases, through rapid diagnosis and reporting, isolation and treatment of cases, contact tracing and individual quarantine, reduction of human mobility and promotion of social distancing measures were implemented in several countries. These interventions contributed to slow down the spread of the disease, suggesting that draconian and nonpharmacological control measures may contain or mitigate the course of the epidemic [3, 4] . However, due to the relaxation of the lockdown rules, interaction between individuals increased during the summer months. Virus circulation continues also in countries with decreasing incidence rates while, a resurgence of COVID-19 has been documented in Europe (https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea). This trend could worsen in the autumn and winter, when changing human behavior might favor and increase transmission of respiratory viruses, such as influenza viruses. Influenza virus and SARS-CoV-2 may have a similar clinical presentations, which is often characterized by fever and dry cough, and transmission modalities [5] . Therefore, co-circulation of these pathogens may complicate the early detection of SARS-CoV-2. The WHO and the Centers for Disease Control and Prevention USA (CDC) encourage testing of samples for influenza from COVID-19 patients, inviting countries to report and register A c c e p t e d M a n u s c r i p t data to regional and global platforms [6, 7] . Additionally, Chinese authorities have also reported the enhancement of infectious disease surveillance systems for both viruses [8] . In this view, monitoring the spread of SARS-CoV-2 and influenza viruses, including the detection of possible co-infections in the community, through the improvement of rapid molecular diagnostic assays, becomes extremely important. To accomplish this specific goal, filling current gaps, we prioritized the development and optimization of two different mix reactions (mix 1 and mix 2) for a multiplex one-step reverse transcriptase (rt) Real Time PCR assay for the detection of SARS-CoV-2 and human seasonal influenza viruses. Three gene targets were used for each mix reaction and probes were labelled with common fluorophores compatible with several Real Time PCR instruments. A panel of clinical samples previously examined for influenza or COVID-19 infections were used for the evaluation of the method. Hereby, we report the results of this study. Primers and probes selected for the detection of Influenza A/ B and SARS-CoV-2 (N2 and E genes) viruses are reported in Table1; each probe was labelled with a different fluorescent reporter dye (FAM, HEX or Cy5). The human ribonuclease P gene (RP constitutive gene) was also included as an internal control. The primer and probe concentrations for all mix reactions were singleton optimized and then combined in the multiplex assay. Protocols were set up using the SensiFAST™ Probe No-ROX One-Step Kit (Bioline) for Roche Real Time PCR (LC480 II), BioRad Real-Time PCR detection systems (CFX96), Stratagene QPCR instrument (MX3000), Rotor Gene Q (Qiagen), and Applied Biosystems TM Real Time PCR systems (7500 Fast, ViiA7). The SensiFAST™ Probe Low-ROX One-Step Kit (Bioline) can be also used for Applied Biosystems apparatus. For singleplex and multiplex assays, primers A c c e p t e d M a n u s c r i p t and probes were used at 400 nM and 100 nM, respectively, while for RP reaction primers and probe were employed in a lower concentration (100nM and 25nM) as shown in Table 1 . Reaction mixture (20μL) contained final concentrations correspondent to: 10 μl of 2X SensiFAST Probe One-Step Mix, each primer and probe at specific concentration, 0.2 μl of reverse transcriptase, 0.4 μl RiboSafe RNase Inhibitor, and 5 μl of nucleic acid. Amplification was performed on different Real Time PCR Systems with the following cycling conditions: 45°C for 20 min followed by 95°C for 10s and 60°C for 30s (45 cycles). Each specimen was also tested for the human ribonuclease P gene (RP constitutive gene) as an internal control (Table 1) . For SARS-CoV-2 an additional mix reaction was performed using N1, N2 and RP gene targets with the identical primers and probe concentrations and thermal cycling protocol (supplementary Table 1 ). Multiplex rt-Real Time PCR assay included two different reaction mixes, namely mix 1 (InfluA, InfluB and E) and mix 2 (N 2 , E and RP) and were set up with different fluorescent dyes (Table 1) . Both mixes ran simultaneously. Mix 1 and mix 2 were conceived for Flu/SARS-CoV-2 screening and for SARS-CoV-2 confirmation, respectively. The mix 2 is required to monitor nucleotide mutations that may occur during the evolving outbreak and that could compromise the sensitivity and specificity of RT-PCR detection. To establish the limit of quantification (LOQ) of each assay, serial dilution containing from 10 7 to 10 0 copies were tested in triplicate over 10 runs. Each singleplex was used as baseline control for the development of the multiplex assay. To assess the specificity of the mix Real Time PCRs, the cross-reactivity of the primer-probe pairs was examined (5 replicates over 10 runs) by combined equal amount of controls ranging from 10 4 to 10 0 copies, and with the only reaction mixture (water, no template control). The endpoint LOQ of each component in the multiplex were directly compared to the single assays using a dilution series of standard and positive controls for each target. Dilutions were tested in triplicate over 10 different runs, and were carried out to guarantee that multiplexing assay did not result in a loss of sensitivity at the endpoint of LOQ, to determine the linearity of the method and for the standard curve production. The threshold cycle number (Ct value) was calculated and each primers-probe set in the single assay was tested, and then combined into mix reactions for multiplex rt-Real Time PCR assay. The inter-assay and intra-assay variability of the multiplex was also assessed to determine the repeatability and the reproducibility of the assay. Each target was tested 10 times at different concentration (10 5 , 10 4 , and 10 3 copies) in one assay (intra-assay) over five separate runs with different users (inter-assay). The potential cross-detection between the viral pathogens was first measured in order to evaluate the assay specificity. Positive controls and synthetic RNA were combined in equal amounts (from 10 3 to 10 0 copy numbers) and used for specificity To determine the efficiency of the multiplex Real Time PCR assay, the Ct values obtained from a series of template RNA dilutions were graphed on the y axis versus the log of the dilution on the x axis. The slope of this line was used to determine the efficiency (E) according to the equation: E = 10 (-1/slope) . To evaluate the assay precision, we calculated the coefficient of variation (CV) as follows: CV% = (standard deviation/mean) × 100. All tests were two-sided and statistically significant differences were assumed when p < 0.05. A c c e p t e d M a n u s c r i p t The sensitivity, specificity, positivity and LOQ was calculated as previously described in the international literature [14, 15] . The optimal cutoff points of the multiplex assay, corresponding to the limit of detection (LOD) of swab samples were statistically established based on receiver operating characteristic (ROC) curve analysis [16] . The ROC analysis was evaluated with a LOD selectivity of 0.95, consistent with the Ct at which at most 5% of truepositive samples scored negative. Accuracy estimation was expressed as agreement percentage (%) defined as true positive or true negative predictive values (PPV and NPV) vs. the singleplex assays known as the "gold standard" [9] [10] [11] [12] [13] . Each target (InfluA, InfluB, E and N2) was tested using standards to determine the sensitivity and the linearity of the method, while the RP gene was included as internal control. Singleplex were performed on LC480II, CFX96, MX3000, Rotor Gene Q, ABI 7500 Fast, ABI ViiA7 Real Time PCR platforms. All instruments showed similar Ct values for all target genes (over-all range 0.2-0.8 ± SD 0.31 and p value <0.05) and the results for the LC480 II are shown in Figure 1 , with marked slope, R 2 , and E values. All the slope values were between −3.311 and −3.469 while the R 2 and E values were > 0.99 and ≥ 97%, respectively for all standard curves. These results suggest that the linearity of the method is consistent, corroborating the robustness of the method. The specificity of primers/probe sets was determined against a panel of pathogens as previously described [7] [8] [9] [10] [11] . However, to assess the specificity of each mix reaction and to exclude artificial non-specific reactivity among combined primer-pairs/probe, oligonucleotides were tested using mixed controls (influenza type M a n u s c r i p t The intra-and inter-assay precision was evaluated by testing three control RNA samples at different concentrations. The precision was determined as a percentage of the coefficient of variation (CV%) of the acquired Ct values. The results are summarized in Table 3 , with the mean Ct and CV values. The intra-plate variability was in line with predetermined Ct samples tested with a CV% range from 0.30% to 0.66%. As expected, the inter-run variability and reproducibility observed with each sample showed a CV% slightly higher (CV % range 0.66%-0.97%). In the latter case, different factors may play small differences between each assay, but the CV% value remains still lower than 1%. Similar findings were found with other Real Time platforms. The results obtained indicate that the developed multiplex assay is highly repeatable, reproducible and robust even at higher Ct values. A c c e p t e d M a n u s c r i p t Influenza viral and SARS-CoV-2 synthetic RNA controls were used in a mixed sample to evaluate the ability of multiplex assay to identify specific viruses. Combinations of different concentration mixtures, from 10 3 to 10 0 copy numbers, were tested by using mix 1 and mix 2 reaction assays, with Ct values reported in Table 4 . Notably, no detection was found for 10 0 copy for all mixes, while all primers/probe sets reacted only with their corresponding target gene, suggesting that this assay is able to detect specifically Influenza A, Influenza B, and SARS-CoV-2 infection from mixed samples. All PCR instruments produced comparable results. As alternative for the mix 2, we set up another mix reaction specific for SARS-CoV-2 using N1, N2 and RP primers and probe [12] . Details and results are reported in the supplementary materials (supplementary Tables 2, 3 and 4) . A total of 800 RNA positive (600 for SARS-CoV-2 and 200 for influenza A/B viruses) and 200 RNA negative swab samples, previously determined by singleplex "gold standard", were tested using the developed multiplex assay. All specimens were confirmed for each specific virus target and only two co-infections (SARS-CoV-2 /influenza A and SARS-CoV-2 /influenza B) were found. Firstly, the Ct value was empirically fixed at 40, but this arbitrary cutoff may be not representative because it may be either too low (false negative results) or too high (falsepositive results). Consequently, on the basis of the sample status (positive or negative), the optimal cutoff point for each target gene was defined by the ROC analysis. As shown in Figure 2 , the optimal cutoff points of the multiplex assay were estimated to be 37.7 for both InfluA and InfluB, and 37.8 for E in the mix 1 reaction, while 37.8 was estimate A c c e p t e d M a n u s c r i p t for N2 and E in the mix 2 reaction. For each target assay the area under a ROC curve (AUC) ranged between 0.998 to 0.999 reflecting an excellent evaluation of the performance of the aggregate quality indicator for the diagnostic assay. Moreover, despite only few positive SARS CoV-2 specimens at Ct >37.8 that were recognized negative (overall 24/800; 3%) in multiplex vs. singleplex "gold standard" assays, the test was proficient to discriminate between the three virus types. Thus, after the designed cutoff Ct values by ROC analysis, parameters for the sensitivity, specificity, PPV, and NPV revealing a high capacity of multiplex assay to differentiate a positive from a negative sample, even when low viral loads were present (Table 5) . Several aspects have favored the pandemic spread of SARS-CoV-2: the high transmissibility, the presence of mild/asymptomatic cases able to spread the disease, the slow development of severe disease, lack of specificity of initial symptoms, and global susceptibility to the infection [17] . After the first wave, which has been interrupted by interventions implemented in many countries in different geographic areas, limited immunity with undefined levels of protection will exist. Thus, until an effective vaccine is developed, the epidemic may reemerge also in areas that have been previously affected. Although, lockdown measures have proved to be effective, it would be difficult to impose again such restrictions in a delicate balance between health, the economy and social life [18] . supposed to persist after the hot season with a possible increase in virus circulation in autumn and winter time, when seasonal influenza virus is usually more active [19] . This may cause over-burdening of hospital services, especially if increasing transmission of both viruses occurs at the same time. Considering that clinical symptoms can be very similar, it is a A c c e p t e d M a n u s c r i p t priority to promote a fast and appropriate differential diagnosis to support clinicians and public health professionals in their public decision making processes [5, 17, 20] . While the SARS-CoV-2 serology may be used in epidemiological studies molecular tests remain the gold standard laboratory diagnostic tools to diagnoses the infection. Up to now, no multiplex Real Time PCR assay has been available for the simultaneous detection of seasonal influenza A, influenza B, and pandemic SARS-CoV-2. In our study, we assessed two different mix reactions using previously described primes and probes [21, 22] . In particular, the mix 1 assay was designed in order to amplify highly conserved regions for all viruses, while the mix 2 allowed the specific detection of SARS- CoV-2 infection. Targeting more than one region in the viral genome for SARS-CoV-2 detection is important to mitigate the risk of loss of sensitivity due to the mutation rate (currently not quantified but presumed to be of concern as this is an RNA virus) during the SARS-CoV-2 outbreak [23] . The two mix reactions (N2/E/RNase P and N1/N2/RNase P) do not have a precise recommendation, but are suggested for laboratories as alternative reaction in the multiplex panel. The findings presented in this study denote that multiplex assay was highly specific and reproducible, showing an elevated sensitivity. The LOQ of each channel (FAM, HEX, or CY5) ranged between 5 to 10 copies/reaction, while the optimal cutoff values determined by ROC analysis were fixed between 37.7 and 37.8. Moreover, it should be highlighted that the molecular protocol was attained by different Real Time instruments with comparable results, obtaining similar performance in terms of specificity and sensitivity on standards and clinical samples. Compared with the singleplex assay, which identifies only one target/reaction, the multiplex test has the advantages of being easy to manage, rapid, and cost-effective. In addition, the human RP gene, as an internal control, allows monitoring the RNA extraction procedure, A c c e p t e d M a n u s c r i p t checking the errors of Real Time PCR handling. The molecular assay is also appropriate to detect co-infections for diagnostic purposes, or to conduct studies in order to assess whether SARS-CoV-2 and influenza co-infection may affect disease evolution and clinical outcomes. Samples tested in this study showed only two co-infections, consistently with the international literature that shows only a few studies reporting infection with both viruses [24] [25] [26] [27] [28] [29] . Despite the evidence of co-infections with other pathogens in COVID-19 patients, little is known about the viral kinetics and dynamics of SARS-CoV-2 co-infections. However, we can hypothesize that mix infections may be linked to mechanisms of viral interference and to the immunological status of each individual [27] . The main limit of our study was the relative low sample size. Although we tested about 1000 clinical specimens, the number of samples positive for influenza specimens was very low. To this regard, it should be considered that the influenza active surveillance activities globally decreased because of the COVID-19 pandemic and a low number of samples were collected during the influenza season (2019-2020) in Italy. Moreover, it should be mentioned that also during the SARS pandemic in 2003, only 5% of mixed infection with influenza viruses was reported, though it tended to increase over the time [30] . Recently the CDC (USA) presented the Flu SC2 diagnostic kit, a quadruplex assay rt-Real Time PCR for Influenza and SARS-CoV-2 viruses, that detects and differentiates RNA from SARS-CoV-2, influenza A virus, and influenza B in upper or lower respiratory specimens [31] . The multiplex protocol gives full instructions for its use and primer/probe sequences are also listed. Moreover, the Flu SC2 kit is addressed to Reference or public health laboratories certified under the Clinical Laboratory Improvement Amendment (CLIA). Several Companies announced the development of Real Time-based commercial kits which are expected to detect SARS-CoV-2, influenza A/B, and other respiratory viruses. Generally, M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t InfluA/FAM --- N2/FAM ---E-HEX ---RP-CY5** § All data were obtained by the LC480 II Roche Real Time PCR platform *No detection ** Data of the RP assay, included in the mix 2, were not part of this analysis A c c e p t e d M a n u s c r i p t Table 5 . Performance with optimal cutoff values of multiplex vs. singleplex "gold standards" assays by WHO/CDC methods. A c c e p t e d M a n u s c r i p t Each assay was tested using related standard ranging from 10 7 to 10 copies/μl. PCR curve data is represented by relative fluorescence plotted against cycle numbers (Ct). Standard curves were generated from the Ct values obtained against known concentrations. Slope of the regression curve, the coefficient of determination (R 2 ) and efficiency (E) are indicated for each assay. COVID-19 Epidemic in the Seine-Saint-Denis Department of Greater Paris: One Month and Three Waves for a Tsunami Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK-ninth update 23 Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency COVID-19 and the next influenza season World Health Organization Coinfection of Influenza virus and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) World Health Organization. WHO information for molecular diagnosis of influenza virus in humans -update. World Health Organization Influenza surveillance from Novel Coronavirus (2019-nCoV) Realtime rRT-PCR Panel Primers and Probes Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Clinical tests: sensitivity and specificity The MIQE guidelines: minimum information for publication of quantitative real-time pcr experiments Determination of the LOQ in real-time PCR by receiver operating characteristic curve analysis: application to qPCR assays for Fusarium verticillioides and F. proliferatum Lessons learned from the 2019-nCoV epidemic on prevention of future infectious diseases Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China No Association of COVID-19 transmission with temperature or UV radiation in Chinese cities Systematic testing for influenza and COVID-19 among patients with respiratory illness Comparative performance of SARS CoV-2 detection assays using seven different primer/probe sets and one assay kit Triplex real-time RT-PCR for severe acute respiratory syndrome coronavirus 2 Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19) Co-infection with SARS-CoV-2 and Influenza A virus in patient with pneumonia COVID-19 patients with recent Influenza A/B infection: a retrospective study The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan Co-infection in SARS-CoV-2 infected patients: where are Influenza virus and rhinovirus/enterovirus? SARS-CoV-2 and influenza virus coinfection Co-infection with COVID-19 and influenza A virus in two died patients with acute respiratory syndrome, Bojnurd, Iran Influenza virologic and epidemiologic surveillance in Guangzhou, 2003. South China CDC. 2020. CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay Laboratory management for SARS-CoV-2 detection: a user-friendly combination of the heat treatment approach and rt-Real-time PCR testing The authors thank Alessia Caratelli, Alessia Possenti, Gianluca Marucci, Simona Cherchi, Alessandra Ludovisi, Stefania Orsini, Trentina Di Muccio, Marina Sbattella and Ambrogio Carlei for giving their time and technical support in sample collection. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.Funding: This work was supported by routine institutional funds. M a n u s c r i p t these molecular tests are run on specific platforms with dedicated cartridges containing all the necessary reagents. Although this packaging makes them easy to perform in the hospital setting, it also may be a limiting factor in a shortage situation, in which, as previously reported for other aspects, an in-house method could be a useful alternative [32] .In conclusion, the Real Time PCR format here described could be a suitable tool for molecular testing with potential for routine surveillance SARS-CoV-2 and influenza viruses.However, it will be necessary to investigate whether the method might be affected by the copresence of other respiratory pathogens in the clinical samples.